KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Inventory (2016 - 2025)

Abbott Laboratories' Inventory history spans 17 years, with the latest figure at $6.5 billion for Q4 2025.

  • For Q4 2025, Inventory rose 4.75% year-over-year to $6.5 billion; the TTM value through Dec 2025 reached $6.5 billion, up 4.75%, while the annual FY2025 figure was $6.5 billion, 4.75% up from the prior year.
  • Inventory for Q4 2025 was $6.5 billion at Abbott Laboratories, down from $6.7 billion in the prior quarter.
  • Across five years, Inventory topped out at $7.0 billion in Q2 2025 and bottomed at $5.2 billion in Q4 2021.
  • The 5-year median for Inventory is $6.5 billion (2023), against an average of $6.2 billion.
  • The largest annual shift saw Inventory increased 19.7% in 2022 before it decreased 5.72% in 2024.
  • A 5-year view of Inventory shows it stood at $5.2 billion in 2021, then rose by 19.7% to $6.2 billion in 2022, then rose by 6.43% to $6.6 billion in 2023, then fell by 5.72% to $6.2 billion in 2024, then increased by 4.75% to $6.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Inventory are $6.5 billion (Q4 2025), $6.7 billion (Q3 2025), and $7.0 billion (Q2 2025).